Skip to content

Price / book at other companies

Exelixis logo
ExelixisEXEL
5.8×+1.0×
Cytokinetics logo
CytokineticsCYTK
58.5×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
6.4×+4.6×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.6×+0.2×
Incyte logo
IncyteINCY
3.3×+0.1×
Summit Therapeutics logo
Summit TherapeuticsSMMT
26.9×-14.4×

Other financials

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+21.1%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-452%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-464%

Valuation

See full
Market cap$8.58B-64.4%
Enterprise value$8.48B-65.0%
P/E181.2×+1.3×
P/S11.2×-24.0×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.2pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Calculated from Corcept Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corcept Therapeutics's price / book?
Corcept Therapeutics (CORT) reported price / book of 6.7× in Q1 2026.
How has Corcept Therapeutics's price / book changed year-over-year?
Corcept Therapeutics's price / book decreased by 61.9% year-over-year, from 17.6× to 6.7×.
What is the long-term trend for Corcept Therapeutics's price / book?
Over 5 years (2020 to 2025), Corcept Therapeutics's price / book has grown at a -0.4% compound annual growth rate (CAGR), from 5.8× to 5.7×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.